Drugs / N(2)-L-Alanine L-Glutamine dipeptide
N(2)-L-Alanine L-Glutamine dipeptide
also known as
Dipeptiven (N(2)-L-Alanine L-Glutamine dipeptide)
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT01478126 | Jan → Dec 2012 | coronary atherosclerosis | Meshalkin Research Institute of Pathology of Circulation | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03341169 | Mar 2018 → Sep 2019 | aortic valve stenosis | Yonsei University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | N(2)-L-Alanine L-Glutamine dipeptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01478126 ↗ |
| Known as | Dipeptiven (N(2)-L-Alanine L-Glutamine dipeptide) | “Dipeptiven (N(2)-L-Alanine L-Glutamine dipeptide)” NCT01478126 ↗ |
| Modality | Peptide | “N(2)-L-Alanine L-Glutamine dipeptide” NCT03341169 ↗ |
| Route | Intravenous | “Intravenous infusion of N (2) -L-alanyl-L-glutamine” NCT03341169 ↗ |